Article ; Online: Combination of omalizumab with allergen immunotherapy versus immunotherapy alone for allergic diseases: A meta-analysis of randomized controlled trials.
International forum of allergy & rhinology
2023 Volume 14, Issue 4, Page(s) 794–806
Abstract: Background: Allergen immunotherapy (AIT)-associated adverse events (AEs) limit its usage in the management of allergic diseases. The monoclonal anti-IgE antibody (omalizumab) and AIT have complementary actions. However, no consensus has been reached on ... ...
Abstract | Background: Allergen immunotherapy (AIT)-associated adverse events (AEs) limit its usage in the management of allergic diseases. The monoclonal anti-IgE antibody (omalizumab) and AIT have complementary actions. However, no consensus has been reached on whether their combination could exert superior efficacy and safety. Objective: To evaluate whether the combination of AIT with omalizumab is superior to AIT alone in treating allergic diseases. Methods: The MEDLINE/PubMed, Embase, Scopus and Cochrane Library databases were searched to identify randomized control trials (RCTs) reporting the outcomes of omalizumab combined with AIT (omalizumab + AIT) versus AIT alone. A random-effect model was established to estimate outcomes with a 95% confidence interval (CI). Results: A total of 11 eligible RCTs (involving 901 patients) were screened out for the meta-analysis. According to a pooled analysis, omalizumab + AIT significantly increased the number of patients achieving the target maintenance dose (TMD) and sustained unresponsiveness (SU) to allergens (odds ratio [OR] = 2.43; 95% CI: 1.33-4.44; p = 0.004; I Conclusion: Omalizumab + AIT can significantly enhance the efficacy and safety of AIT by increasing TMD and SU to allergens, while decreasing severe systemic AEs. |
---|---|
MeSH term(s) | Humans ; Omalizumab/therapeutic use ; Randomized Controlled Trials as Topic ; Desensitization, Immunologic/adverse effects ; Allergens ; Hypersensitivity/etiology |
Chemical Substances | Omalizumab (2P471X1Z11) ; Allergens |
Language | English |
Publishing date | 2023-09-16 |
Publishing country | United States |
Document type | Meta-Analysis ; Journal Article |
ZDB-ID | 2625826-2 |
ISSN | 2042-6984 ; 2042-6976 |
ISSN (online) | 2042-6984 |
ISSN | 2042-6976 |
DOI | 10.1002/alr.23268 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.A 6927: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.